Catalyst

Slingshot members are tracking this event:

New Analyses: Adding SPIRIVA RESPIMAT Effective for Uncontrolled Asthma - Regardless of Allergy Subtype

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
Boehringer Ingelheim Community voting in process

Additional Information

Additional Relevant Details
The addition of SPIRIVA RESPIMAT significantly improved lung function. Adding SPIRIVA RESPIMAT also was shown to improve asthma symptom control, as measured by the seven question Asthma Control Questionnaire (ACQ-7) and reduce the risk of asthma worsening and exacerbations. The ACQ-7 results in the pooled analysis did not distinguish among the treatment arms."The data confirm that adding SPIRIVA RESPIMAT is a well-tolerated and effective treatment option for asthma patients independent of allergic subtype," said Mark Vandewalker, MD, director, Clinical Research of the Ozarks, Columbia, Missouri. "For people with allergic asthma who are still experiencing symptoms, adding SPIRIVA RESPIMAT may help open airways to improve breathing."People living with allergic asthma – the most common form of the condition – experience inflammation and a tightening of the airways due to exposure to common allergens. These patients may need other inhaled options that complement their existing therapy.
http://www.prnewswir...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 07, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Asthma Exacerbations, Immunoglobulin E, Ige, Eosinophil Levels, Primotina-asthma, Mezzotina-asthma, Unitina-asthma